Insilico's Lung Drug Reverses Aging Markers in Study
THE SO WHAT
An AI-discovered lung drug showing reversal of biological aging markers is a proof point for AI-native pipelines in drug discovery, not just tooling around the edges. Biotech operators should assume regulators and partners will increasingly ask whether you can generate — and validate — similar AI-first candidates, not just incremental screens.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechLongsys Founder Bets Big on R&D to Ride AI Memory Wave
Longsys earmarking 78% of proceeds for R&D to move from module house to memory brand shows how AI demand is pulling component makers up the stack. If you depend on commodity memory pricing, model more volatility — differentiated AI-optimized SKUs will command margin while generic parts see sharper cycles.
Deep & Emerging TechAmerican data centers in just seven states are reportedly using more water than all the cities in California
Water is becoming as constraining as power for hyperscale and AI buildouts—10.4 million acre-feet across seven states reframes siting as a hydrology problem, not just a grid problem. If you're planning AI-heavy capacity, you now need a water-risk map alongside your power and latency maps.
Deep & Emerging TechGPUThor breaks the error correction Nvidia recommended against Rowhammer
GPUThor punching through ECC on Nvidia GPUs turns Rowhammer from a theoretical GPU risk into a live one—model hosts now have to assume memory corruption attacks can ride on their accelerator fleet. If you’re serving sensitive workloads on shared GPUs, treat isolation, firmware patching, and anomaly detection as urgent, not optional.
Deep & Emerging TechBelgian chip researcher held since May over secrets allegedly sent to China
Chip IP is now treated as national-security-grade—this Belgian case underscores how export controls are being enforced at the individual researcher level, not just at corporate or state channels. Multinational R&D teams in semis need tighter data access, travel, and collaboration controls or they’ll find compliance risk sitting inside their labs.